JPWO2020180501A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020180501A5
JPWO2020180501A5 JP2021543384A JP2021543384A JPWO2020180501A5 JP WO2020180501 A5 JPWO2020180501 A5 JP WO2020180501A5 JP 2021543384 A JP2021543384 A JP 2021543384A JP 2021543384 A JP2021543384 A JP 2021543384A JP WO2020180501 A5 JPWO2020180501 A5 JP WO2020180501A5
Authority
JP
Japan
Prior art keywords
polypeptide
amino acid
acid sequence
mhc class
presenting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021543384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022522404A (ja
JP7691927B2 (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/019244 external-priority patent/WO2020180501A1/en
Publication of JP2022522404A publication Critical patent/JP2022522404A/ja
Publication of JPWO2020180501A5 publication Critical patent/JPWO2020180501A5/ja
Application granted granted Critical
Publication of JP7691927B2 publication Critical patent/JP7691927B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021543384A 2019-03-06 2020-02-21 Ｔ細胞調節抗原提示ポリペプチド及びその使用方法 Active JP7691927B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814715P 2019-03-06 2019-03-06
US62/814,715 2019-03-06
PCT/US2020/019244 WO2020180501A1 (en) 2019-03-06 2020-02-21 T-cell modulatory antigen-presenting polypeptides and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022522404A JP2022522404A (ja) 2022-04-19
JPWO2020180501A5 true JPWO2020180501A5 (enExample) 2023-03-01
JP7691927B2 JP7691927B2 (ja) 2025-06-12

Family

ID=72338064

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021543384A Active JP7691927B2 (ja) 2019-03-06 2020-02-21 Ｔ細胞調節抗原提示ポリペプチド及びその使用方法

Country Status (4)

Country Link
US (1) US20220106378A1 (enExample)
EP (1) EP3935079A4 (enExample)
JP (1) JP7691927B2 (enExample)
WO (1) WO2020180501A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3558339T (pt) 2016-12-22 2024-03-15 Cue Biopharma Inc Polipeptídeos multiméricos moduladores de células t e métodos de utilização dos mesmos
CA3054955A1 (en) 2017-03-15 2018-09-20 Cue Biopharma, Inc. Methods for modulating an immune response
HUE069314T2 (hu) 2017-04-28 2025-03-28 Nat Jewish Health Módszer a rheumatoid arthritis kezelésére a HLA gén RNS-vezérelt genomszerkesztésének felhasználásával
CA3074839A1 (en) 2017-09-07 2019-03-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptide with conjugation sites and methods of use thereof
WO2021231376A2 (en) 2020-05-12 2021-11-18 Cue Biopharma, Inc. Multimeric t-cell modulatory polypeptides and methods of use thereof
WO2022226054A2 (en) * 2021-04-21 2022-10-27 Cue Biopharma, Inc. Antigen presenting polypeptide complexes bearing tgf-beta and methods of use thereof
AU2022261908A1 (en) * 2021-04-21 2023-10-05 Cue Biopharma, Inc. Mhc class ii t-cell modulatory polypeptides for treating type 1 diabetes mellitus (t1d) and methods of use thereof
CN117751136A (zh) * 2021-05-10 2024-03-22 科罗拉多州立大学董事会法人团体 用于治疗自身免疫的工程化hla等位基因
US20240270815A1 (en) * 2021-05-26 2024-08-15 Cue Biopharma, Inc. Antigen Presenting Polypeptide Complexes and Methods of Use Thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
CA2115742A1 (en) 1991-08-20 1993-03-04 Ronald G. Crystal Adenovirus mediated transfer of genes to the gastrointestinal tract
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
AU687829B2 (en) 1993-06-24 1998-03-05 Advec, Inc. Adenovirus vectors for gene therapy
JP3875990B2 (ja) 1993-10-25 2007-01-31 カンジ，インコーポレイテッド 組換えアデノウイルスベクターおよび使用方法
CA2196085C (en) * 1994-07-29 2002-12-10 Hing C. Wong Mhc complexes and uses thereof
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
US6287860B1 (en) 2000-01-20 2001-09-11 Isis Pharmaceuticals, Inc. Antisense inhibition of MEKK2 expression
US6811785B2 (en) * 2001-05-07 2004-11-02 Mount Sinai School Of Medicine Of New York University Multivalent MHC class II—peptide chimeras
EP1578917A4 (en) 2001-07-19 2008-01-23 Perlan Therapeutics Inc MULTIMEDIA PROTEINS AND METHODS FOR THE PRODUCTION AND USE THEREOF
US10105437B2 (en) 2004-04-28 2018-10-23 Btg International Limited Epitopes related to coeliac disease
EP1996220B2 (en) 2006-03-06 2023-08-16 Amunix Operating Inc. Unstructured recombinant polymers and uses thereof
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
BRPI0815416A2 (pt) 2007-08-15 2014-10-21 Amunix Inc Composições e métodos para modificar propriedades de polipeptídeos biologicamente ativos
EA020843B1 (ru) 2009-02-03 2015-02-27 Амуникс Оперейтинг Инк. Удлиненные рекомбинантные полипептиды и содержащие их композиции
US9695410B2 (en) * 2010-07-15 2017-07-04 Technion Research & Development Foundation Limited Isolated high affinity entities with T-cell receptor like specificity towards native complexes of MHC class II and glutamic acid decarboxylase (GAD) autoantigenic peptides
US10816554B2 (en) * 2014-04-04 2020-10-27 The Board Of Trustees Of The Leland Stanford Junior University Ligand discovery for T cell receptors
CA2946887A1 (en) 2014-04-24 2015-10-29 Immusant, Inc. Compositions comprising gluten peptides and uses thereof
US20170058015A1 (en) * 2014-06-18 2017-03-02 Albert Einstein College Of Medicine, Inc. Syntac polypeptides and uses thereof
HUE045466T2 (hu) * 2014-11-06 2019-12-30 Hoffmann La Roche Fc-régió-variánsok módosított FcRn-kötéssel és alkalmazási eljárások
WO2016198932A2 (en) * 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy
US20190046648A1 (en) * 2016-03-03 2019-02-14 Cue Biopharma, Inc. T-cell modulatory multimeric polypeptides and methods of use thereof
CN109689096A (zh) * 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
JP2020500015A (ja) * 2016-11-09 2020-01-09 ユーティーアイ リミテッド パートナーシップ 組換えｐＭＨＣクラスＩＩ分子
AU2018328283A1 (en) * 2017-09-07 2020-02-20 Cue Biopharma, Inc. Antigen-presenting polypeptides and methods of use thereof
JP2023541366A (ja) * 2020-09-09 2023-10-02 キュー バイオファーマ， インコーポレイテッド １型真性糖尿病（ｔ１ｄ）を治療するためのｍｈｃクラスｉｉ ｔ細胞調節多量体ポリペプチド及びその使用方法

Similar Documents

Publication Publication Date Title
JP2021500855A5 (enExample)
Born et al. Recognition of a peptide antigen by heat shock--reactive γδ T lymphocytes
AU2018259029B2 (en) TCR and peptides
Todd et al. A molecular basis for genetic susceptibility to insulin-dependent diabetes mellitus
RU2752528C2 (ru) Композиции и библиотеки, содержащие рекомбинантные полинуклеотиды, кодирующие Т-клеточные рецепторы, и способы применения рекомбинантных Т-клеточных рецепторов
IL95125A (en) T cell peptides receive a method for their selection and preparation, and pharmaceutical preparations containing them
Tabata et al. Characterization of self-glutamic acid decarboxylase 65-reactive CD4+ T-cell clones established from Japanese patients with insulin-dependent diabetes mellitus
JPWO2020180501A5 (enExample)
NO308611B1 (no) AnalogifremgangsmÕte for fremstilling av et terapeutisk aktivt peptid
US6464978B1 (en) Vaccination and methods against multiple sclerosis resulting from pathogenic responses by specific T cell populations
EP3898665B1 (en) Cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies
NO317049B1 (no) Undertrykkelse av T-celleproliferasjon ved anvendelse av fragmenter av myelinbasisk protein
CN114302962A (zh) 特异性针对来源于ebv抗原的tcr构建体
Antonsson et al. Functional characterization of the interaction between the superantigen staphylococcal enterotoxin A and the TCR.
JPWO2020181062A5 (enExample)
KR100369286B1 (ko) Mhc단백질의원핵세포내발현
EP0286447B1 (en) Method and agents relating to prophylactic treatment of autoimmune diseases
JP2003524369A (ja) エピトープを有する主要組織適合複合体クラスｉｉエレメント／免疫グロブリンキメラ分子
Abromson-Leeman et al. T cell responses to myelin basic protein in experimental autoimmune encephalomyelitis-resistant BALB/c mice
CN100364611C (zh) 肽基免疫治疗剂
Adams et al. Human T-cell clones to the 70-kilodalton heat shock protein of Mycobacterium leprae define mycobacterium-specific epitopes rather than shared epitopes
AU2756792A (en) Method of producing antibodies to a restricted population of t lymphocytes, antibodies and method of use
Kuhröber et al. Vaccination with T cell receptor peptides primes anti‐receptor cytotoxic T lymphocytes (CTL) and anergizes T cells specifically recognized by these CTL
JPWO2022056014A5 (enExample)
CN117651711A (zh) 使用免疫原性肽的改进的治疗方法